Healthcare / Drug Manufacturers - Specialty & GenericWarsaw
$20.65
+0.25 (+1.23%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-11.3M · quality 54.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
9/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.1B
P/E
10.1x
↓EV/EBITDA
N/A
•ROE
-21.8%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
-0.30x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-79.4M · FCF $23.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | — | — | $177.5M | $164.4M | $161.9M | $169.6M |
| Net Income | $-79.4M | $-79.4M | $-34.4M | $-28.1M | $-39.3M | — |
| EBITDA | $-24.9M | $-24.9M | $-36.8M | $32.7M | $9.3M | — |
| EPS | -1.49 | -1.49 | -0.64 | -0.55 | -0.77 | — |
| Gross Margin | — | — | 64.4% | 59.4% | 59.0% | 63.6% |
| Operating Margin | — | — | -20.7% | -18.9% | -23.5% | — |
| Net Margin | — | — | -19.4% | -17.1% | -24.3% | — |
| Balance Sheet | ||||||
| Debt/Equity | — | — | 0.04 | 0.06 | 0.06 | — |
| Current Ratio | 1.90 | 1.90 | — | — | — | — |
| Cash Flow | ||||||
| Free Cash Flow | $23.9M | $23.9M | $-11.3M | $-41.1M | $-38.6M | — |
| Returns | ||||||
| ROE | -21.8% | -21.8% | -7.7% | -6.3% | -8.2% | — |
| Valuation | ||||||
| P/E | 10.12 | 10.12 | — | — | — | — |
| EV/EBITDA | — | — | — | 24.46 | 76.12 | — |
| P/B | 3.03 | 3.03 | 3.21 | 1.81 | 1.60 | — |
| Growth & Yield | ||||||
| Revenue Growth | — | — | 8.0% | 1.5% | -4.5% | — |
| EPS Growth | -132.8% | -132.8% | -16.4% | 28.6% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-6.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.64 → -1.49
Residual
-6.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.